PVH
6.10.2020 18:02:13 CEST | Business Wire | Press release
PVH Europe, the global headquarters of Tommy Hilfiger and the European offices of Calvin Klein, both owned by PVH Corp. [NYSE: PVH], announces the installation of what is believed to be the world’s most powerful* currently operational solar roof at its state-of-the-art Warehouse and Logistics Center in Venlo, the Netherlands. Generated by more than 48,000 solar panels, the solar roof covers the Center’s electricity footprint, as well as indirectly providing 100% of all energy for PVH Europe’s warehouses, offices and stores in the Netherlands via the Dutch public power network. PVH Europe’s energy partner, Eneco, has certified that all energy needed to power these buildings is generated by the new rooftop installation. The Venlo Warehouse and Logistics Center is owned by Heylen Warehouses, a Belgian logistics real estate company, in a joint venture with AG Real Estate, and retained IZEN as the technical installation partner for the roof.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201006005513/en/
This milestone marks another step in PVH’s journey to procure 100% of its electricity from renewable sources for its offices, warehouses and stores, and to drive a 30% reduction in supply chain carbon emissions by 2030. This work is linked to PVH’s science-based emissions target aligned with the most ambitious level of decarbonization as set out by the Paris Agreement. It is also one of the priorities outlined in the company’s Forward Fashion corporate responsibility strategy, which aims to reduce negative impacts to zero, increase positive impacts to 100% and improve the over 1 million lives across the company’s value chain.
Key Facts:
- The Venlo warehouse is PVH Europe’s main distribution center covering 110,000m2 .
- Awarded a BREEAM (Building Research Establishment Environmental Assessment Method) sustainability rating of “Very Good”.
- The world’s most powerful solar roof, with a capacity to generate 18 MWp (megawatt peak).
- Facilitated by over 48,000 high performance solar panels.
- Fully powers all PVH Europe owned stores, warehouses and offices in the Netherlands.
“This is an incredible milestone for our Warehouse and Logistics Center in Venlo and for PVH Europe’s sustainability journey,” said Martijn Hagman, CEO ,Tommy Hilfiger Global and PVH Europe. “We have participated in the installation of what we believe is now the world’s most powerful, fully operational solar roof – a huge stride in our commitment to be powered by 100% renewable electricity by 2030 and reduce supply chain emissions by 30% by 2030. This would not have been possible without a best-in-class team of such talented, passionate, and devoted PVH associates.”
At present, up to 600,000 pieces of TOMMY HILFIGER and CALVIN KLEIN product are distributed daily from the PVH Europe Warehouse and Logistics Center in Venlo to points of sale, including owned and operated stores in Europe, the Middle East and Africa, and direct to customers. The warehouse’s Very Good rating by BREEAM incorporates exemplary standards for energy, water, transport, materials, waste, pollution, ecology, health and well-being. This is reflected through energy efficient lighting in 100% of the space, the use of 100% FSC (Forest Stewardship Council) certified packaging and 100% recycling of all cardboard, plastics and printed material.
PVH is a member of RE100, the corporate renewable electricity initiative led by the Climate Group, and has committed to RE100 to procure 100% of its electricity from renewable sources by 2030.
Sam Kimmins, Head of RE100 at the Climate Group said: “Congratulations to PVH on the finalization of the Venlo solar rooftop. This is another exciting step in their global work and partnership towards their 2025 RE100 target. It raises the bar once more for on-site renewables.”
“ We believe that logistic buildings will be the next generation of solar power plants,” said Philippe Deschilder, CEO of Heylen Warehouses. “The partnership with PVH Europe for the solar roof project supports our ambition to invest in renewable energy, creating added value for our customers by enabling them to reduce their carbon footprint.”
About PVH Corp.
PVH is one of the most admired fashion and lifestyle companies in the world. We power brands that drive fashion forward – for good. Our brand portfolio includes the iconic CALVIN KLEIN , TOMMY HILFIGER , Van Heusen , IZOD , ARROW, Warner’s , Olga and Geoffrey Beene brands, as well as the digital-centric True&Co. intimates brand. We market a variety of goods under these and other nationally and internationally known owned and licensed brands. PVH has over 40,000 associates operating in over 40 countries and $9.9 billion in annual revenues. That's the Power of Us. That’s the Power of PVH.
Follow us on Facebook , Instagram , Twitter and LinkedIn .
About RE100
RE100 is a global initiative bringing together the world’s most influential businesses committed to 100% renewable power. Led by the Climate Group in partnership with CDP , the group has a total revenue of over US$5.4 trillion and operates in a diverse range of sectors. Together, they send a powerful signal to policymakers and investors to accelerate the transition to a clean economy. #RE100
*PVH defines the “world’s most powerful solar roof” as the most powerful solar roof that is currently operational and installed on one singular structure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005513/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom